Journals / art / 2018 / Cilt: 33 - Sayı: 2

Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions

Journal
art
Pages
108–127
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that this paper provides Turkish physicians dealing with PsA patients a practical guide in their routine clinical practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to establish the first national treatment recommendations by the Turkish League Against Rheumatism (TLAR) for psoriatic arthritis (PsA) based on the current evidence.
📊
Key Findings & Data:The TLAR expert committee consisted of 13 rheumatologists and 12 physical medicine and rehabilitation specialists experienced in the treatment and care of patients with PsA from 22 centers.
💡
Conclusion & Impact:We believe that this paper provides Turkish physicians dealing with PsA patients a practical guide in their routine clinical practice.
🔬Design:Review & Systematic Survey
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to establish the first national treatment recommendations by the Turkish League Against Rheumatism (TLAR) for psoriatic arthritis (PsA) based on the current evidence. Materials and methods: A systematic literature review was performed regarding the management of PsA. The TLAR expert committee consisted of 13 rheumatologists and 12 physical medicine and rehabilitation specialists experienced in the treatment and care of patients with PsA from 22 centers. The TLAR recommendations were built on those of European League Against Rheumatism (EULAR) 2015. Levels of evidence and agreement were determined. Results: Recommendations included five overarching principles and 13 recommendations covering therapies for PsA, particularly focusing on musculoskeletal involvement. Level of agreement was greater than eight for each item. Conclusion: This is the first paper that summarizes the recommendations of TLAR as regards the treatment of PsA. We believe that this paper provides Turkish physicians dealing with PsA patients a practical guide in their routine clinical practice.

🔖

Cite This Article

NAS, K., KILIÇ, E., ÇEVİK, R., BODUR, H., ATAMAN, Ş., AYHAN, F., AKGÜL, Ö., AKINCI, A., ALTAY, Z., ÇAPKIN, E., DAĞLI, A. Z., DURUÖZ, M. T., GÜRER, G., GÖĞÜŞ, F. N., GARİP, Y., KAÇAR, C., KAMANLI, A., KAPTANOĞLU, E., KAYA, T., KOCABAŞ, H., ÖZDEMİREL, E. A., Sum, S. (2018). Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions. art, Cilt: 33 - Sayı: 2, 108–127. https://ajindex.com/articles/151917

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, doubleblind, non-inferiority trial. Lancet 2017;389:2304-16.
  2. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
  3. Kristensen LE, Lie E, Jacobsson LT, Christensen R, Mease PJ, Bliddal H, et al. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cwohort Study from Southern Sweden. J Rheumatol 2016;43:81-7.
  4. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rodevand E, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013;72:1840-4.
  5. Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor a inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013;65:1213-23.
  6. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebocontrolled trial. Gut. 2012;61:1693-700.
  7. Kawalec P, Mocko P, Malinowska-Lipien I, Brzostek T. Efficacy and safety of ustekinumab in the induction therapy of TNF-alpha-refractory Crohn's disease patients: a systematic review and meta-analysis. J Comp Eff Res 2017;6:601-12.
  8. Zhou Z, Dai C, Liu WX. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis. Hepatogastroenterology 2015;62:829-37.
  9. Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, et al. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One 2016;11:e0165435. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gu